Skip to main content
padlock icon - secure page this page is secure

BADBIR — an update on progress and developments

Buy Article:

$42.32 + tax (Refund Policy)

Biologic therapies are an important new treatment option for patients with moderate to severe psoriasis, however, their long-term safety has not been evaluated in this disease group. In 2008, the British Association of Dermatologists (BAD) set up a register — the BAD Biologic Interventions Register (BADBIR) — to investigate the long-term outcome of psoriasis patients treated with biologic agents, and thus to better assess the risks associated with such treatments. A previous article in this journal (McElhone K and Jackson K, 2008) provided an introduction to this register and explained the rationale. This article will provide an update on the progress and developments of BADBIR.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: March 1, 2011

More about this publication?
  • Dermatological Nursing is the quarterly, peer-reviewed journal of the British Dermatological Nursing Group (BDNG) and the UK's only quality dermatological nursing journal. It aims to provide cutting-edge articles on the treatment and management of dermatological conditions and the care of patients with skin problems. While the focus is on dermatological nursing, the information included is relevant to other healthcare professionals.
  • Membership Information
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more